Serum Institute of India Ltd. -- the world’s biggest vaccine maker by volume and AstraZeneca Plc’s local partner -- have engaged in months of haggling behind closed doors and are yet to sign a formal supply agreement.
That has left at least 70 million vaccine doses in limbo despite the urgent need in a country facing the world’s second-largest outbreak.Also Read | The race to take fashion retail onlineOn Sunday, Serum’s billionaire Chief Executive Officer Adar Poonawalla said Indian officials have “orally" agreed to buy 100 million doses at a “special price" of 200 rupees ($2.74) a shot, below the about $4 to $5 price tag given to the U.K.